BioCardia, Inc. (BCDA) News
Track canonical SquawkNews coverage tagged to BCDA, BioCardia, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 10 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
BioCardia confirms Q4 2026 PMDA Shonin submission plans, Helix De Novo pre-submission to FDA
BioCardia confirmed Q4 2026 timing for a PMDA Shonin submission for CardiAMP and plans a De Novo pre-submission to the FDA for Helix this quarter.Key Highlights:Original SEC Filing: BioCardia, Inc. [ BCDA ] - 8-K - Sep.
REGULATION | Sep 23, 2026, 01:24 PM UTC
L
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
SUNNYVALE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided a
REGULATION | Sep 23, 2026, 01:21 PM UTC
L
BCDA - BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
BCDA - BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
REGULATION | Sep 23, 2026, 01:15 PM UTC
L
BioCardia to present CardiAMP updates at H.C. Wainwright
BioCardia said it will present CardiAMP regulatory progress, the ongoing CardiAMP HF II pivotal trial and Helix and Heart3D platform updates at the H.C. Wainwright conference.
EQUITY | Sep 10, 2026, 12:33 PM UTC
L
BCDA - BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference - Click F
BCDA - BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 10, 2026, 12:30 PM UTC
M
BioCardia says FDA confirms Helix catheter meeting minutes
BioCardia says the FDA confirmed meeting minutes supporting a follow-on de novo pre-submission for approval of its Helix transendocardial delivery catheter, and it plans to submit the pre-submission this quarter.
REGULATION | Aug 24, 2026, 12:57 PM UTC
L
BioCardia (BCDA) FDA confirms Helix catheter meeting minutes for De Novo
BioCardia (BCDA) says the FDA confirms meeting minutes supporting a follow-on De Novo pre-submission for approval for its Helix transendocardial delivery catheter.
REGULATION | Aug 24, 2026, 12:30 PM UTC
L
BCDA Reports Q2 2026 Results
BioCardia reports second quarter 2026 business highlights and financial results
EARNINGS | Aug 12, 2026, 08:08 PM UTC
L
BCDA - BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026
BCDA - BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026
EARNINGS | Aug 05, 2026, 07:16 PM UTC
M
Insiders Buy COR, KYN, AMS
Insiders purchase shares of COR, KYN, AMS, and other companies
EQUITY | Jun 25, 2026, 09:47 AM UTC